Literature DB >> 22894960

The regulatory T cells in anti-influenza antibody response post influenza vaccination.

Shih-Min Wang1, Ming-Hsun Tsai, Huan-Yao Lei, Jen-Ren Wang, Ching-Chuan Liu.   

Abstract

The efficacy and effectiveness of influenza vaccines depend primarily on the vaccine recipient and the virus similarity to the endemic virus. Regulatory T cells (Tregs) and cytokines are known to restrict immune responses against viral infections. We conducted this study to explore the role of Tregs, cytokines, and antibody production after influenza vaccination. The whole blood was collected from healthy subjects (n = 36) before and two weeks after influenza vaccine immunization for two or three consecutive years. The cell surface markers, intracellular staining of Foxp3(+) Tregs, and Th1/Th2 cytokines were determined. The antibody titer was detected using the hemagglutination inhibition test. The CD3(+), CD127(+), CD4(+)CD25(+) and CD4(+)Foxp3(+) cells were increased significantly post vaccination. The plasma level of the transforming growth factor (TGF-β), but not interleukin (IL)-2, IL-4, IL-5, IL-10, IFN-γ, TNF-α, was also found to increase significantly after vaccination. We further correlated the cytokine fold-increases with the anti-influenza antibody titer for individual post vaccination. It was found that the IL-10 level after vaccination correlated with the fold-increases of anti-H1N1, anti-H3N2, anti-B/Yamagata, and anti-B/Victoria antibodies. But, a negative relationship occurs between the TGF-β level and fold-increases of anti-H1N1, anti-H3N2, anti-B/Yamagata, and anti-B/Victoria antibodies post vaccination. Treg cells and TGF-β seem to participate in the downregulation of the anti-influenza antibody response post influenza vaccination. Alteration of Treg activity might enhance influenza vaccine antibody responses and efficacy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22894960      PMCID: PMC3579905          DOI: 10.4161/hv.21117

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  32 in total

1.  A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice.

Authors:  Noelia Casares; Francesc Rudilla; Laura Arribillaga; Diana Llopiz; José Ignacio Riezu-Boj; Teresa Lozano; Jacinto López-Sagaseta; Laura Guembe; Pablo Sarobe; Jesús Prieto; Francisco Borrás-Cuesta; Juan José Lasarte
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

2.  Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness.

Authors:  Y Hirota; M Kaji; S Ide; J Kajiwara; K Kataoka; S Goto; T Oka
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

Review 3.  Determinants of immunity to influenza infection in man.

Authors:  C W Potter; J S Oxford
Journal:  Br Med Bull       Date:  1979-01       Impact factor: 4.291

4.  Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice.

Authors:  Madhav D Sharma; De-Yan Hou; Babak Baban; Pandelakis A Koni; Yukai He; Phillip R Chandler; Bruce R Blazar; Andrew L Mellor; David H Munn
Journal:  Immunity       Date:  2010-12-09       Impact factor: 31.745

5.  Reconstitution of a functional interleukin (IL)-7 receptor demonstrates that the IL-2 receptor gamma chain is required for IL-7 signal transduction.

Authors:  S E Ziegler; K K Morella; D Anderson; N Kumaki; W J Leonard; D Cosman; H Baumann
Journal:  Eur J Immunol       Date:  1995-02       Impact factor: 5.532

6.  Origin of regulatory T cells with known specificity for antigen.

Authors:  Irina Apostolou; Adelaida Sarukhan; Ludger Klein; Harald von Boehmer
Journal:  Nat Immunol       Date:  2002-07-01       Impact factor: 25.606

7.  Responses to influenza vaccination in different T-cell subsets: a comparison of healthy young and older adults.

Authors:  J E McElhaney; C M Upshaw; J W Hooton; K E Lechelt; G S Meneilly
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

8.  Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells.

Authors:  Susan M Kaech; Joyce T Tan; E John Wherry; Bogumila T Konieczny; Charles D Surh; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-11-16       Impact factor: 25.606

Review 9.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

Authors:  Shimon Sakaguchi
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  12 in total

1.  Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage.

Authors:  Shahzma Merani; George A Kuchel; Alison Kleppinger; Janet E McElhaney
Journal:  Exp Gerontol       Date:  2017-09-27       Impact factor: 4.032

2.  A pilot study showing differences in glycosylation patterns of IgG subclasses induced by pneumococcal, meningococcal, and two types of influenza vaccines.

Authors:  Anne Cathrine Vestrheim; Anders Moen; Wolfgang Egge-Jacobsen; Leon Reubsaet; Trine Grønhaug Halvorsen; Diane Bryant Bratlie; Berit Smestad Paulsen; Terje Einar Michaelsen
Journal:  Immun Inflamm Dis       Date:  2014-05-22

3.  H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance.

Authors:  Rui Liu; Leonard Moise; Ryan Tassone; Andres H Gutierrez; Frances E Terry; Kotou Sangare; Matthew T Ardito; William D Martin; Anne S De Groot
Journal:  Hum Vaccin Immunother       Date:  2015-06-19       Impact factor: 3.452

4.  Modulation of gut microbiota and delayed immunosenescence as a result of syringaresinol consumption in middle-aged mice.

Authors:  Si-Young Cho; Juewon Kim; Ji Hae Lee; Ji Hyun Sim; Dong-Hyun Cho; Il-Hong Bae; Hyunbok Lee; Min A Seol; Hyun Mu Shin; Tae-Joo Kim; Dae-Yong Kim; Su-Hyung Lee; Song Seok Shin; Sin-Hyeog Im; Hang-Rae Kim
Journal:  Sci Rep       Date:  2016-12-15       Impact factor: 4.379

5.  Impact of ageing and a synbiotic on the immune response to seasonal influenza vaccination; a randomised controlled trial.

Authors:  Sumia Enani; Agnieszka Przemska-Kosicka; Caroline E Childs; Catherine Maidens; Honglin Dong; Lorenza Conterno; Kieran Tuohy; Susan Todd; Margot Gosney; Parveen Yaqoob
Journal:  Clin Nutr       Date:  2017-01-28       Impact factor: 7.324

6.  Effect of homeostatic T-cell proliferation in the vaccine responsiveness against influenza in elderly people.

Authors:  M Leal; Y M Pacheco; I Herrero-Fernández; I Rosado-Sánchez; A I Álvarez-Ríos; M I Galvá; M De Luna-Romero; S Sanbonmatsu-Gámez; M Pérez-Ruiz; J M Navarro-Marí; A Carrillo-Vico; B Sánchez; R Ramos; J Cañizares
Journal:  Immun Ageing       Date:  2019-07-05       Impact factor: 6.400

7.  Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice.

Authors:  Weiping Cao; Jin Hyang Kim; Adrian J Reber; Mary Hoelscher; Jessica A Belser; Xiuhua Lu; Jacqueline M Katz; Shivaprakash Gangappa; Martin Plante; David S Burt; Suryaprakash Sambhara
Journal:  Vaccine       Date:  2017-05-09       Impact factor: 3.641

8.  Immunophenotype expressions and cytokine profiles of influenza A H1N1 virus infection in pediatric patients in 2009.

Authors:  Shih-Min Wang; Yu-Ting Liao; Yu-Shiang Hu; Tzong-Shiann Ho; Ching-Fen Shen; Jen-Ren Wang; Yee-Shin Lin; Ching-Chuan Liu
Journal:  Dis Markers       Date:  2014-02-18       Impact factor: 3.434

Review 9.  Regulatory T cells as adjuvant target for enhancing the viral disease vaccine efficacy.

Authors:  Jagadeesh Bayry
Journal:  Virusdisease       Date:  2013-11-29

Review 10.  Influenza in Asthmatics: For Better or for Worse?

Authors:  Raja Veerapandian; John D Snyder; Amali E Samarasinghe
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.